Glen Eagle Advisors, LLC Regenxbio Inc. Transaction History
Glen Eagle Advisors, LLC
- $546 Billion
- Q2 2024
A detailed history of Glen Eagle Advisors, LLC transactions in Regenxbio Inc. stock. As of the latest transaction made, Glen Eagle Advisors, LLC holds 150 shares of RGNX stock, worth $1,678. This represents 0.0% of its overall portfolio holdings.
Number of Shares
150
Previous 250
40.0%
Holding current value
$1,678
Previous $7.46 Million
76.48%
% of portfolio
0.0%
Previous 0.01%
Shares
10 transactions
Others Institutions Holding RGNX
# of Institutions
197Shares Held
43.2MCall Options Held
58.9KPut Options Held
58.4K-
Black Rock Inc. New York, NY8.61MShares$96.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.11MShares$57.2 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.57MShares$51.1 Million3.49% of portfolio
-
Jpmorgan Chase & CO New York, NY3.01MShares$33.7 Million0.0% of portfolio
-
State Street Corp Boston, MA2.87MShares$32.2 Million0.0% of portfolio
About REGENXBIO Inc.
- Ticker RGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,230,000
- Market Cap $484M
- Description
- REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...